ID: hyp-sda-2026-04-01-001-3
Hypothesis
Temporal TREM2 Pathway Modulation
Stage-specific TREM2 pathway targeting based on disease progression with biomarker-guided intervention timing.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Stage-specific TREM2 pathway targeting based on disease progression with biomarker-guided intervention timing
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Disease Stage Assessment<br/>Plasma CSF Biomarker Panel"]
B["Early AD Stage<br/>Low Amyloid Tau Burden"]
C["Late AD Stage<br/>High Amyloid Tau Burden"]
D["TREM2 Agonist Treatment<br/>AL002c Anti-TREM2 Antibody"]
E["TREM2 Pathway Modulation<br/>TYROBP-SYK-PI3K Signaling"]
F["Microglial Phagocytosis Enhanced<br/>Amyloid Plaque Clearance"]
G["Anti-Inflammatory Phenotype<br/>DAM Homeostatic Balance"]
H["TREM2 Partial Antagonist<br/>Reduce Excessive Microglial Activation"]
I["Neuroprotection via Timing<br/>AD Progression Slowed"]
A --> B
A --> C
B --> D
C --> H
D --> E
E --> F
F --> G
H --> G
G --> I
style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style I fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53.
Supports
TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge.
Supports
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Supports
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ['TREM2'
No curated PDB or AlphaFold mapping for ['TREM2' yet. Search RCSB →
💉 Clinical Trials (5)
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
UNKNOWN·NCT05419596 · Istanbul University
Cognitive Dysfunction
Urologic Surgery
COMPLETED·NCT06224920 · Ludwig-Maximilians - University of Munich
Alzheimer Disease Corticobasal Syndrome
magnetic resonance imaging electroencephalography blood and CSF biomarker
RECRUITING·NCT06274528 · Washington University School of Medicine
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo
COMPLETED·NCT04388254 · Cassava Sciences, Inc.
Alzheimer Disease
Simufilam 100 mg oral tablet Placebo
COMPLETED·NCT04570644 · AZTherapies, Inc.
Healthy Volunteers Alzheimer Disease
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ['TREM2', 'TYROBP'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0580
Events (7d)
1
Price History
▼8.2%💾 Resource Usage
LLM Tokens
14,692
$0.0882
Total Cost
$0.0882
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF TREM2/TYROBP pathway agonism is administered to 5xFAD mice at early disease stage (characterized by low plasma soluble TREM2 and minimal plaque deposition), THEN microglial phagocytic activity will | Increased microglial clustering at amyloid plaques (CD68+IBA1+ co-localization >40% above baseline), 30% reduction in Thioflavin-S+ plaque area, and improved pe | — no observation — | pending | 0.75 |
| IF TREM2/TYROBP pathway agonism is administered to 5xFAD mice at late disease stage (characterized by high plasma soluble TREM2 and extensive plaque deposition), THEN neuroinflammatory markers (IL-1β, | No statistically significant improvement in spatial memory (Morris water maze latency difference <10% from vehicle), no reduction in IL-1β or TNF-α cortical lev | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF TREM2/TYROBP pathway agonism is administered to 5xFAD mice at early disease stage (characterized by low plasma soluble TREM2 and minimal plaque deposition), THEN microglial phagocytic activity will increase by >40% (measured by CD68+IBA1+ cell density at plaques) and amyloid plaque burden will de
Predicted outcome: Increased microglial clustering at amyloid plaques (CD68+IBA1+ co-localization >40% above baseline), 30% reduction in Thioflavin-S+ plaque area, and i
Falsification: If TREM2/TYROBP agonism at early disease stage fails to demonstrate statistically significant improvement in microglial phagocytosis markers OR fails to reduce amyloid burden OR shows no cognitive ben
pendingconf 72%
IF TREM2/TYROBP pathway agonism is administered to 5xFAD mice at late disease stage (characterized by high plasma soluble TREM2 and extensive plaque deposition), THEN neuroinflammatory markers (IL-1β, TNF-α, Iba1+ microglial Coverage Index) will show no significant improvement (<10% change) and cogn
Predicted outcome: No statistically significant improvement in spatial memory (Morris water maze latency difference <10% from vehicle), no reduction in IL-1β or TNF-α co
Falsification: If TREM2/TYROBP agonism at late disease stage produces significant cognitive improvement (>20% reduction in escape latency), significant reduction in pro-inflammatory cytokines (>30%), or clear microg
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.